FATE1 and adrenal cortex neoplasm: The presence of circulating antibodies directed against FATE1 was assessed in a cohort of adult patients with adrenocortical tumors from three different ENSAT centers (46 malignant—among these, six patients had a pre-surgery and a post-surgery sample available for analysis—and 10 benign).